- Home
- MIST vs PROK Comparison
MIST vs PROK Comparison
Compare MIST & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- PROK
- Stock Information
- Founded
- MIST 2003
- PROK 2015
- Country
- MIST Canada
- PROK United States
- Employees
- MIST N/A
- PROK N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIST Health Care
- PROK Health Care
- Exchange
- MIST Nasdaq
- PROK Nasdaq
- Market Cap
- MIST 89.8M
- PROK 85.5M
- IPO Year
- MIST N/A
- PROK N/A
- Fundamental
- Price
- MIST $1.60
- PROK $4.74
- Analyst Decision
- MIST Strong Buy
- PROK Buy
- Analyst Count
- MIST 2
- PROK 4
- Target Price
- MIST $7.50
- PROK $5.33
- AVG Volume (30 Days)
- MIST 1.8M
- PROK 33.2M
- Earning Date
- MIST 08-07-2025
- PROK 08-08-2025
- Dividend Yield
- MIST N/A
- PROK N/A
- EPS Growth
- MIST N/A
- PROK N/A
- EPS
- MIST N/A
- PROK N/A
- Revenue
- MIST N/A
- PROK $306,000.00
- Revenue This Year
- MIST N/A
- PROK $54.34
- Revenue Next Year
- MIST N/A
- PROK N/A
- P/E Ratio
- MIST N/A
- PROK N/A
- Revenue Growth
- MIST N/A
- PROK N/A
- 52 Week Low
- MIST $0.63
- PROK $0.46
- 52 Week High
- MIST $2.75
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- MIST 83.15
- PROK 92.14
- Support Level
- MIST $1.86
- PROK $0.54
- Resistance Level
- MIST $1.97
- PROK $7.13
- Average True Range (ATR)
- MIST 0.14
- PROK 0.62
- MACD
- MIST 0.06
- PROK 0.47
- Stochastic Oscillator
- MIST 100.00
- PROK 68.59
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.